Chagas Cardiomyopathy
Mostrando 13-24 de 98 artigos, teses e dissertações.
-
13. ERRATUM: Chagas Disease Cardiomyopathy
Int. J. Cardiovasc. Sci.. Publicado em: 01/04/2019
-
14. Renal dysfunction in Leishmaniasis and Chagas disease coinfection: a case report
ABSTRACT Visceral leishmaniasis (VL) is an endemic parasitic disease frequently found in Northeast Brazil and may cause acute kidney injury (AKI) and glomerulonephritis. After appropriate treatment, renal function recovery may occur. We describe the rare case of a patient with VL, who developed severe AKI requiring dialysis and was subsequently diagnosed wit
Rev. Inst. Med. trop. S. Paulo. Publicado em: 14/11/2018
-
15. Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy
BACKGROUND The anti-inflammatory and cardioprotective properties of curcumin (Cur), a natural polyphenolic flavonoid isolated from the rhizomes of Curcuma longa, are increasingly considered to have beneficial effects on the progression of Chagas heart disease, caused by the protozoan parasite Trypanosoma cruzi. OBJECTIVE To evaluate the effects of oral t
Mem. Inst. Oswaldo Cruz. Publicado em: 16/07/2018
-
16. Single nucleotide polymorphisms of cytokine-related genes and association with clinical outcome in a Chagas disease case-control study from Brazil
BACKGROUND The severity of chronic chagasic cardiomyopathy (CCC), the most frequent clinical outcome of Chagas disease (CD), has been associated with cytokine-enriched heart tissue inflammation, and high serum levels of transforming growth factor (TGFβ), interferon-gamma (IFNγ), and tumour necrosis factor (TNF). Conversely, increased interleukin (IL)-10 s
Mem. Inst. Oswaldo Cruz. Publicado em: 14/05/2018
-
17. Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland
BACKGROUND Chronic cardiomyopathy occurs in 20-40% of the patients with Chagas disease. Autoimmune mechanisms may contribute to its pathogenesis. We diagnosed several cases of systemic autoimmune diseases among Bolivian migrants in Geneva with a high prevalence of Chagas disease. OBJECTIVES We tested the hypothesis of a clinical association between systemi
Mem. Inst. Oswaldo Cruz. Publicado em: 05/02/2018
-
18. A Forma Indeterminada da Doença de Chagas
Arq. Bras. Cardiol.. Publicado em: 2018-02
-
19. Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy: a Survival Analysis
Abstract Introduction: Chagas disease represents an important health problem with socioeconomic impacts in many Latin-American countries. It is estimated that 20% to 30% of the people infected by Trypanosoma cruzi will develop chronic Chagas cardiomyopathy (CCC), which is generally accompanied by heart failure (HF). Cardiac resynchronization therapy (CRT) m
Braz. J. Cardiovasc. Surg.. Publicado em: 2018-02
-
20. Ex vivo T-lymphocyte chemokine receptor phenotypes in patients with chronic Chagas disease
Abstract INTRODUCTION: Elucidating the molecules involved in the inflammatory process of chronic Chagas disease may allow identification of treatment targets. METHODS: The ex vivo phenotypic expression of chemokine receptors CCR1, CCR3, CCR4, CCR5, CXCR2, CXCR3, CXCR4, and CXCR5 on the CD4+ and CD8+ T-cells of patients with chronic Chagas cardiomyopathy
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-09
-
21. Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis
BACKGROUND As chronic Chagas disease does not have a definitive treatment, the development of alternative therapeutic protocols is a priority. Dipyridamole (DPY) is an alternative to counteract the pathophysiological phenomena involved in Chagas cardiomyopathy. OBJECTIVE To evaluate the therapeutic efficacy of DPY associated with nifurtimox (Nfx) in epim
Mem. Inst. Oswaldo Cruz. Publicado em: 2017-09
-
22. Association of caspase-1 polymorphisms with Chagas cardiomyopathy among individuals in Santa Cruz, Bolivia
Abstract INTRODUCTION: Trypanosoma cruzi (Tc) infection is usually acquired in childhood in endemic areas, leading to Chagas disease, which progresses to Chagas cardiomyopathy in 20-30% of infected individuals over decades. The pathogenesis of Chagas cardiomyopathy involves the host inflammatory response to T. cruzi, in which upstream caspase-1 activation p
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-08
-
23. Bone marrow cell migration to the heart in a chimeric mouse model of acute chagasic disease
BACKGROUND Chagas disease is a public health problem caused by infection with the protozoan Trypanosoma cruzi. There is currently no effective therapy for Chagas disease. Although there is some evidence for the beneficial effect of bone marrow-derived cells in chagasic disease, the mechanisms underlying their effects in the heart are unknown. Reports have
Mem. Inst. Oswaldo Cruz. Publicado em: 2017-08
-
24. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
Chagas cardiomyopathy is the most frequent and most severe manifestation of chronic Chagas disease, and is one of the leading causes of morbidity and death in Latin America. Although the pathogenesis of Chagas cardiomyopathy is incompletely understood, it may involve several mechanisms, including parasite-dependent myocardial damage, immune-mediated myocardi
Mem. Inst. Oswaldo Cruz. Publicado em: 16/02/2017